BioPharma Resources

Drug Trial Radar · NCT06395103

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

LIGHTBEAM-U01 Substudy 01A: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors

Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

90

Planned (sponsor's estimate)

Start

Aug 16, 2024

Primary completion

Mar 31, 2029

Study completion Mar 31, 2029

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
May 1, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 months, up to 25 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL)/Burkitt lymphoma, or neuroblastoma and in pediatric and young adult participants with Ewing sarcoma.

Conditions

  • B-cell Acute Lymphoblastic Leukemia
  • Diffuse Large B-cell Lymphoma
  • Burkitt Lymphoma
  • Neuroblastoma
  • Ewing Sarcoma

Interventions

  • Zilovertamab vedotinBiological

    Administered via IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Number of Participants from 1 to <18 years of Age Who Experience a Dose-Limiting Toxicity (DLT)Time frame: Up to 42 days
  2. Part 1: Number of Participants from 1 to <18 years of Age Who Experience One or More Adverse Events (AEs)Time frame: Up to approximately 54 months
  3. Part 1: Number of Participants from 1 to <18 years of Age Who Discontinue Study Treatment Due to AEsTime frame: Up to approximately 54 months
  4. Part 1: Number of Participants from 1 to <18 years of Age Who Receive Dose Modification Due to AEsTime frame: Up to approximately 54 months
  5. Part 1 and Part 2: Objective Response (OR) for Participants with B-Cell Acute Lymphoblastic Leukemia (B-ALL)Time frame: Up to approximately 54 months
  6. Part 1 and Part 2: OR for Participants with Diffuse Large B-Cell Lymphoma (DLBCL)/Burkitt Lymphoma, Neuroblastoma, and Ewing SarcomaTime frame: Up to approximately 54 months

Locations

71 sites in 23 countries. Site status is shown where the registry gives one.

  • Children's Hospital Los Angeles ( Site 1006)

    Los Angeles, California · Recruiting

  • Children's Hospital Colorado-Center for Cancer and Blood Disorders ( Site 1016)

    Aurora, Colorado · Recruiting

  • Yale New Haven Hospital ( Site 1012)

    New Haven, Connecticut · Recruiting

  • Johns Hopkins All Children's Hospital ( Site 1025)

    St. Petersburg, Florida · Recruiting

  • University of Iowa Health Care. ( Site 1017)

    Iowa City, Iowa · Recruiting

  • Dana-Farber Cancer Institute ( Site 1013)

    Boston, Massachusetts · Recruiting

  • Corewell Health ( Site 1001)

    Grand Rapids, Michigan · Recruiting

  • Children's Mercy Hospital ( Site 1024)

    Kansas City, Missouri · Recruiting

  • Rutgers Cancer Institute of New Jersey ( Site 1008)

    New Brunswick, New Jersey · Recruiting

  • Memorial Sloan Kettering Cancer Center ( Site 1010)

    New York, New York · Recruiting

  • New York Medical College ( Site 1023)

    Valhalla, New York · Recruiting

  • Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 1003)

    Fargo, North Dakota · Recruiting

  • Oregon Health and Science University ( Site 1004)

    Portland, Oregon · Recruiting

  • Children's Hospital of Philadelphia (CHOP) ( Site 1021)

    Philadelphia, Pennsylvania · Recruiting

  • Sanford Children's Hospital-Sanford Children's Specialty Clinic ( Site 1015)

    Sioux Falls, South Dakota · Recruiting

  • University of Texas MD Anderson Cancer Center ( Site 1007)

    Houston, Texas · Recruiting

  • Intermountain - Primary Children's Hospital ( Site 1014)

    Salt Lake City, Utah · Recruiting

  • Sydney Children's Hospital ( Site 1997)

    Randwick, New South Wales, Australia · Recruiting

  • Queensland Children's Hospital-Oncology & Haematology ( Site 1996)

    Brisbane, Queensland, Australia · Recruiting

  • Royal Children's Hospital-Children's Cancer Centre ( Site 1994)

    Melbourne, Victoria, Australia · Recruiting

  • UZ Gent ( Site 1428)

    Ghent, Oost-Vlaanderen, Belgium · Recruiting

  • Hospital Erasto Gaertner-CEPEP - Pesquisa Clínica ( Site 1268)

    Curitiba, Paraná, Brazil · Completed

  • Hospital de Clinicas de Porto Alegre ( Site 1265)

    Porto Alegre, Rio Grande do Sul, Brazil · Recruiting

  • Fundação Pio XII - Hospital de Câncer de Barretos ( Site 1264)

    Barretos, São Paulo, Brazil · Recruiting

  • Fundação Faculdade Regional de Medicina de São José do Rio Preto-Centro Integrado de Pesquisa ( Site 1267)

    São José do Rio Preto, São Paulo, Brazil · Recruiting

  • Alberta Children's Hospital ( Site 1227)

    Calgary, Alberta, Canada · Recruiting

  • The Hospital for Sick Children ( Site 1225)

    Toronto, Ontario, Canada · Recruiting

  • McGill University Health Centre-Pediatric HematologyOncology ( Site 1223)

    Montreal, Quebec, Canada · Recruiting

  • Hospital Clínico Regional Dr. Guillermo Grant Benavente ( Site 1881)

    Concepción, Biobio, Chile · Recruiting

  • Hospital Luis Calvo Mackenna ( Site 1879)

    Santiago, Region M. de Santiago, Chile · Recruiting

  • Hospital Carlos Van Buren ( Site 1880)

    Valparaíso, Valparaiso, Chile · Recruiting

  • Hospital Pablo Tobon Uribe ( Site 1923)

    Medellín, Antioquia, Colombia · Recruiting

  • Clinica de la Costa S.A.S.-Clinical Research Oncology & Hematology -Pediatric ( Site 1924)

    Barranquilla, Atlántico, Colombia · Recruiting

  • IMAT S.A.S ( Site 1921)

    Montería, Departamento de Córdoba, Colombia · Recruiting

  • Detska nemocnice FN Brno ( Site 1388)

    Brno, Brno-mesto, Czechia · Recruiting

  • Fakultni nemocnice v Motole-Klinika detske hematologie a onkologie ( Site 1387)

    Prague, Praha 5, Czechia · Recruiting

  • Rigshospitalet-Department of paediatrics and adolescent medicine, Section of Paed haem-onc ( Site 1467)

    Copenhagen, Capital Region, Denmark · Recruiting

  • CHU de Bordeaux. Hopital Pellegrin ( Site 1105)

    Bordeaux, Aquitaine, France · Recruiting

  • CENTRE LEON BERARD-IHOPE (pediatrric oncology) ( Site 1100)

    Lyon, Auvergne-Rhône-Alpes, France · Recruiting

  • Gustave Roussy ( Site 1103)

    Villejuif, Île-de-France Region, France · Recruiting

Showing 40 of 71 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.